Details
Ipigrix Indications
- diseases of the peripheral nervous system: mono- and polyneuropathy, myasthenia gravis and myasthenic syndrome of various etiologies;
- diseases of the central nervous system (CNS): bulbar paralysis and paresis; recovery period organic CNS lesions accompanied by motor disorders.
Contraindications
- Hypersensitivity to the components of the drug;
- Epilepsy;
- Extrapyramidal hyperkinesis violations;
- Angina, severe bradycardia;
- Asthma;
- Vestibular disorders;
- Gastric ulcer or duodenal ulcer in the acute stage;
- Mechanical intestinal obstruction and urinary tract.
Dosage & Administration
Dosage and duration of treatment is determined individually depending on the severity of the disease. Ipidakrynu solution containing 5 mg / ml and 15 mg / ml administered intramuscularly or subcutaneously.
Diseases of the peripheral nervous system.
Mono and polyneuropathy of various origins, subcutaneously or intramuscularly injected 5-15 mg 1-2 times a day, a course of treatment - 10-15 days (in severe cases - up to 30 days); further treatment continues tablet form of the drug.
Myasthenia gravis and myasthenic syndrome subcutaneously or intramuscularly injected 5-30 mg 1-3 times a day with the subsequent transition to tablet form. The total course of treatment is 1-2 months. If necessary, treatment can be repeated several times with a break between courses of 1-2 months.
The disease of the central nervous system.
Bulbar paralysis and paresis, subcutaneous and intramuscular injected 5-15 mg 1-2 times a day, a course of treatment - 10-15 days, with the possibility of switching to tablet form.
Recovery period for organic CNS lesions.
Intramuscular - 10-15 mg 1-2 times a day, a course of treatment - 15 days, more if possible - 1-2 times a day.
